Lupin bags tentative USFDA nod for HIV-1 infection drugs

This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries.

Emtricitabine and Tenofovir Alafenamide Tablets are indicated to treat or prevent HIV-1 infection in adults and children who weigh at least 35 kg.

Read also: Lupin gets USFDA tentative nod for Sodium Sulfate, Magnesium Sulfate, Potassium Chloride Tablets

Mr. Naresh Gupta, President - API and Global Institution Business, Lupin said, “Lupin is committed to offering affordable, quality treatments for patients. The tentative approval from the U.S. FDA for our Emtricitabine and Tenofovir Alafenamide Tablets significantly enhances our HIV medicine offering.”

Read also: Lupin, Huons ink pact for registration, marketing of Cyclosporine Ophthalmic Nanoemulsion in Mexico

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally,

Read also: Lupin alliance partner ForDoz gets USFDA nod for Doxorubicin Hydrochloride Liposome Injection